Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 6751: In situ vaccination with Flt3l gene modified CD103+ type 1 conventional dendritic cells synergizes with anti-PD-1 checkpoint blockade in murine models of non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJensen AbascalRLRaymond J. LimRSRamin Salehi‐Rad

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Abascal et al. (2024) studied this question.

synapsesocial.com/papers/68e72e1db6db6435876a731dhttps://doi.org/10.1158/1538-7445.am2024-6751
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 1182: PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti- PD-1 treatment in patients with non-small cell lung cancer2024
  2. 2FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis 23842025
  3. 3Abstract CT153: Phase I trial of intratumoral administration of autologous <i>CCL21</i> gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injections2024 · 1 citations
  4. 4Abstract 2476: Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity2024
  5. 5Abstract 6664: In situ vaccination with hyper-interferon sensitive influenza induces adaptive immune response and sensitizes murine non-small cell lung cancer to PD-1 blockade2024